Anatomy of the Spleen and Pathology of Hypersplenism

  • Masayoshi KageEmail author
  • Reiichirou Kondou
  • Toshirou Ogata


The functions of the spleen are hemofiltration, purification, and immune function, but for a long time, the spleen has been said to be a mysterious organ with many unknown features remaining to be elucidated, such as the pathology of hypersplenism in portal hypertension.

In this chapter, firstly, the structure and function of the spleen are explained. In addition, the pathomorphology of splenomegaly in patients with liver cirrhosis and idiopathic portal hypertension (IPH) is explained. Liver cirrhosis and IPH share the histology of chronic congestive lesions, but differences have also been reported.

Splenectomy and partial splenic embolization (PSE) to treat hypersplenism in cirrhotic patients are reviewed. Splenectomy and PSE have provided many benefits, such as improvement of hypersplenism, portal hypertension, and liver function, completion of interferon therapy and liver cancer treatment, and improvement of immunity, which may contribute to the prognosis of cirrhotic patients. Generally, splenectomy is considered to reduce immunocompetence and leads to infection susceptibility, but improvement of immunocompetence by splenectomy is rather expected in cirrhotic patients.


Spleen Pathology Portal hypertension Liver cirrhosis Idiopathic portal hypertension Hypersplenism Splenectomy 


  1. 1.
    Schmidt EE, Macdonald IC, Groom AC. Microcirculatory pathways in normal human spleen, demonstrated by scanning electron microscopy of corrosion casts. Am J Anat. 1988;181:253–66.CrossRefGoogle Scholar
  2. 2.
    Misawa T. Induction of experimental splenomegaly with portal hypertension in rats with liver cirrhosis. Nihon Shokakibyo Gakkai Zasshi. 1991;88:2653–62.PubMedGoogle Scholar
  3. 3.
    Nakagawa S. The spleen—idiopathic portal hypertension. Clin All Around. 1984;9:1781–6.Google Scholar
  4. 4.
    Kage M, Takasu O, Ogata T, et al. Investigation on portal hemodynamic—Changes of marginal zone in portal hypertension spleen. The Ministry of Health Research Project for Japan Intractable Disease Project on Aberrant Portal Hemodynamics Research Report in 2008; 2009. p. 70–3.Google Scholar
  5. 5.
    Dhiman RK, Chawla Y, Vasishta RK, et al. Non-cirrhotic portal fibrosis (idiopathic portal hypertension): experience with 151 patients and a review of the literature. J Gastroenterol Hepatol. 2002;17:6–16.CrossRefGoogle Scholar
  6. 6.
    Tokushige K, Hirose S, Nishimura H, et al. Abnormal T cell activation and skewed T cell receptor V beta repertoire usage in Japanese patients with idiopathic portal hypertension. Clin Immunol Immunopathol. 1995;75:206–13.CrossRefGoogle Scholar
  7. 7.
    Sato Y, Sawada S, Kozaka K, et al. Significance of enhanced expression of nitric oxide syntheses in splenic sinus lining cells in altered portal hemodynamics of idiopathic portal hypertension. Dig Dis Sci. 2007;52:1987–94.CrossRefGoogle Scholar
  8. 8.
    Yamamoto K. Morphological studies of the spleen in splenomagalic liver cirrhosis comparing with the spleen in idiopathic portal hypertension (so called Banti’s syndrome without liver cirrhosis). Acta Pathol Jpn. 1978;28:891–905.PubMedGoogle Scholar
  9. 9.
    Maesawa C, Sakuma T, Sato T, et al. Structural characteristic of splenic sinuses in idiopathic portal hypertension. Pathol Int. 1995;45:642–8.CrossRefGoogle Scholar
  10. 10.
    Ogata T, Okuda K, Sato T, et al. Long-term outcome of splenectomy in advanced cirrhotic patients with hepatocellular carcinoma and thrombocytopenia. Kurume Med J. 2013;60:37–45.CrossRefGoogle Scholar
  11. 11.
    Nomura Y, Kage M, Ogata T, et al. Influence of splenectomy in patients with liver cirrhosis and hypersplenism. Hepatol Res. 2014;44(10):E100–9.CrossRefGoogle Scholar
  12. 12.
    Kercber KW, Carbonell AM, Heniford BT, et al. Laparoscopic splenectomy reverses thrombocytopenia in patients with hepatitis C cirrhosis and portal hypertension. J Gastrointest Surg. 2004;8:120–6.CrossRefGoogle Scholar
  13. 13.
    Sugawara Y, Yamamoto J, Shimada K, et al. Splenectomy in patients with hepatocellular carcinoma and hypersplenism. J Am Coll Surg. 2000;190:446–50.CrossRefGoogle Scholar
  14. 14.
    Hashizume M, Tomikawa M, Akahoshi T, et al. Laparoscopic splenectomy for portal hypertension. Hepatogastroenterology. 2002;49:847–52.PubMedGoogle Scholar
  15. 15.
    Morinaga A, Ogata T, Kage M, et al. Comparison of liver regeneration after a splenectomy and splenic artery ligation in a dimethylnitrosamine-induced cirrhotic rat model. HPB. 2010;12:22–30.CrossRefGoogle Scholar
  16. 16.
    Kondo R, Kage M, Ogata T, et al. Therapeutic efficacy of splenectomy is attenuated by necroinflammation of the liver in patients with liver cirrhosis. J Hepatobiliary Pancreat Sci. 2015;22:217–24.CrossRefGoogle Scholar
  17. 17.
    Cao ZX, Chen XP, Wu ZD. Changes of immune function in patients with liver cirrhosis after splenectomy combined with resection of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2003;2:562–5.PubMedGoogle Scholar
  18. 18.
    Levi D, Maurino E, Abecasis R, et al. Splenic hypofunction in cirrhosis is not increased risk for infections. Eur J Gastroenterol Hepatol. 1996;8:257–60.CrossRefGoogle Scholar
  19. 19.
    Hashimoto N, Shimoda S, Kawanaka H, et al. Modulation of CD4+ T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis. Clin Exp Immunol. 2011;165:243–50.CrossRefGoogle Scholar
  20. 20.
    Yoshida H, Mamada Y, Taniai N, et al. Partial splenic embolization. Hepatol Res. 2008;38:225–33.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Masayoshi Kage
    • 1
    Email author
  • Reiichirou Kondou
    • 2
  • Toshirou Ogata
    • 3
  1. 1.Kurume University Research Center for Innovative Cancer TherapyKurumeJapan
  2. 2.Department of PathologyKurume University, School of MedicineKurumeJapan
  3. 3.Department of SurgerySt. Mary’s HospitalKurumeJapan

Personalised recommendations